5 Best Performing Biotech ETFs in 2024

4. iShares Biotechnology ETF (NASDAQ:IBB)

5-Year Share Price Performance as of April 20: 16.13%

The iShares Biotechnology ETF (NASDAQ:IBB) seeks to replicate the investment performance of the NYSE Biotechnology Index, composed of American equities within the biotechnology sector. As of April 18, the fund boasts $6.91 billion in net assets, with an expense ratio of 0.45%.

Among its top holdings is Amgen, Inc. (NASDAQ:AMGN), headquartered in Thousand Oaks, California. Amgen is a leading biotechnology company specializing in discovering, developing, manufacturing, and delivering innovative human therapeutics, focusing on areas with significant unmet medical needs. On February 6, Amgen, Inc. (NASDAQ:AMGN) released its financial results for Q4 2023, reporting a 20% year-over-year increase in revenues to $8.2 billion and a net income of $767 million. The normalized EPS for the quarter stood at $4.71, exceeding the consensus by $0.12.

In the fourth quarter of 2023, 69 out of the 933 hedge funds examined by Insider Monkey held shares of Amgen Inc. (NASDAQ:AMGN). The largest stake was held by Josh Overdeck and David Siegel’s Two Sigma Advisors, valued at $333 million.